November 23, 2016 - By Louis Casey · 0 Comments
The stock of Aduro Biotech Incorporated (NASDAQ:ADRO) registered a decrease of 5.06% in short interest. ADRO’s total short interest was 7.49M shares in November as published by FINRA. Its down 5.06% from 7.89 million shares, reported previously. With 407,500 shares average volume, it will take short sellers 18 days to cover their ADRO’s short positions. The short interest to Aduro Biotech Incorporated’s float is 30.25%. About 47,865 shares traded hands. Aduro BioTech Inc (NASDAQ:ADRO) has declined 4.30% since April 21, 2016 and is downtrending. It has underperformed by 9.63% the S&P500.
Aduro Biotech, Inc. is a clinical-stage immunotherapy company. The company has a market cap of $902.28 million. The Firm is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. It currently has negative earnings. The Firm has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted , Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies.
Out of 6 analysts covering Aduro Biotech (NASDAQ:ADRO), 3 rate it a “Buy”, 1 “Sell”, while 2 “Hold”. This means 50% are positive. Aduro Biotech has been the topic of 9 analyst reports since August 19, 2015 according to StockzIntelligence Inc. Oppenheimer downgraded the stock to “Perform” rating in Tuesday, December 1 report. Oppenheimer initiated Aduro BioTech Inc (NASDAQ:ADRO) on Tuesday, October 20 with “Outperform” rating. The stock of Aduro BioTech Inc (NASDAQ:ADRO) earned “Outperform” rating by FBR Capital on Tuesday, May 17. The stock has “Hold” rating given by Zacks on Thursday, September 3. The rating was maintained by Roth Capital with “Buy” on Tuesday, November 24. The stock has “” rating given by Leerink Swann on Wednesday, August 19. The rating was maintained by Roth Capital with “Buy” on Thursday, August 27. Bank of America downgraded it to “Underperform” rating and $14 target price in Tuesday, March 15 report. The stock of Aduro BioTech Inc (NASDAQ:ADRO) earned “Buy” rating by TH Capital on Tuesday, November 24.
Aduro Biotech, Inc., incorporated on May 5, 2011, is a clinical-stage immunotherapy company. The Firm is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Firm has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies. The Company’s LADD technology platform is engineered to express tumor-associated antigens to induce specific and targeted immune responses. Based on compelling clinical data in advanced cancers, LADD technology platform is being developed as a treatment for multiple indications, including pancreatic, ovarian, lung and prostate cancers, mesothelioma and glioblastoma. The Company’s STING Pathway Activator platform is designed to activate the intracellular STING receptor, resulting in a tumor-specific immune response. The Company’s B-select monoclonal antibody platform includes various immune modulating assets in research and preclinical development.
Another recent and important Aduro BioTech Inc (NASDAQ:ADRO) news was published by Nasdaq.com which published an article titled: “Is Aduro BioTech (ADRO) Stock A Solid Choice Right Now?” on November 22, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Louis Casey